PE20010913A1 - Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas - Google Patents

Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas

Info

Publication number
PE20010913A1
PE20010913A1 PE2000001266A PE0012662000A PE20010913A1 PE 20010913 A1 PE20010913 A1 PE 20010913A1 PE 2000001266 A PE2000001266 A PE 2000001266A PE 0012662000 A PE0012662000 A PE 0012662000A PE 20010913 A1 PE20010913 A1 PE 20010913A1
Authority
PE
Peru
Prior art keywords
ethyl
trifluoromethyl
acid
quinoline
dihydro
Prior art date
Application number
PE2000001266A
Other languages
English (en)
Spanish (es)
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010913A1 publication Critical patent/PE20010913A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2000001266A 1999-11-30 2000-11-28 Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas PE20010913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
PE20010913A1 true PE20010913A1 (es) 2001-09-10

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001266A PE20010913A1 (es) 1999-11-30 2000-11-28 Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas

Country Status (44)

Country Link
US (1) US6313142B1 (cg-RX-API-DMAC7.html)
EP (1) EP1125929B1 (cg-RX-API-DMAC7.html)
JP (1) JP3579345B2 (cg-RX-API-DMAC7.html)
KR (1) KR100408177B1 (cg-RX-API-DMAC7.html)
CN (1) CN1173953C (cg-RX-API-DMAC7.html)
AP (1) AP2000002011A0 (cg-RX-API-DMAC7.html)
AR (1) AR029775A1 (cg-RX-API-DMAC7.html)
AT (1) ATE315028T1 (cg-RX-API-DMAC7.html)
AU (1) AU784694B2 (cg-RX-API-DMAC7.html)
BG (1) BG105009A (cg-RX-API-DMAC7.html)
BR (1) BR0005636A (cg-RX-API-DMAC7.html)
CA (1) CA2327029C (cg-RX-API-DMAC7.html)
CO (1) CO5261552A1 (cg-RX-API-DMAC7.html)
CY (1) CY1104989T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20004407A3 (cg-RX-API-DMAC7.html)
DE (1) DE60025317T2 (cg-RX-API-DMAC7.html)
DK (1) DK1125929T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3079A1 (cg-RX-API-DMAC7.html)
EA (1) EA003668B1 (cg-RX-API-DMAC7.html)
EE (1) EE200000659A (cg-RX-API-DMAC7.html)
ES (1) ES2254109T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20022798B (cg-RX-API-DMAC7.html)
GT (1) GT200000190A (cg-RX-API-DMAC7.html)
HN (1) HN2000000203A (cg-RX-API-DMAC7.html)
HR (1) HRP20000804A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0004747A3 (cg-RX-API-DMAC7.html)
ID (1) ID28489A (cg-RX-API-DMAC7.html)
IL (1) IL139849A (cg-RX-API-DMAC7.html)
IS (1) IS5715A (cg-RX-API-DMAC7.html)
MA (1) MA25223A1 (cg-RX-API-DMAC7.html)
NO (1) NO20006039L (cg-RX-API-DMAC7.html)
NZ (1) NZ508509A (cg-RX-API-DMAC7.html)
OA (1) OA11494A (cg-RX-API-DMAC7.html)
PA (1) PA8503801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20010913A1 (cg-RX-API-DMAC7.html)
PL (1) PL344208A1 (cg-RX-API-DMAC7.html)
SG (1) SG102603A1 (cg-RX-API-DMAC7.html)
SK (1) SK17792000A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN00230A1 (cg-RX-API-DMAC7.html)
TW (1) TW591016B (cg-RX-API-DMAC7.html)
UA (1) UA65615C2 (cg-RX-API-DMAC7.html)
UY (1) UY26451A1 (cg-RX-API-DMAC7.html)
YU (1) YU71500A (cg-RX-API-DMAC7.html)
ZA (1) ZA200006947B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
MXPA04005864A (es) * 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
DE60323954D1 (de) * 2002-04-11 2008-11-20 Roar Holding Llc Ex-vivo-verfahren zur bestimmung der cetp-aktivität und der wirksamkeit der behandlung von herzerkrankungen
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
WO2004078730A2 (en) * 2003-03-04 2004-09-16 Takasago International Corporation Method for producing optically active amines
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
CA2519432C (en) * 2003-03-17 2009-06-09 Japan Tobacco Inc. Pharmaceutical compositions comprising cetp inhibitors and a water-insoluble concentration-enhancing additive for the treatment of cardiovascular disease
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
EP2098512A1 (en) * 2003-10-08 2009-09-09 Eli Lilly & Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
EP1861372A1 (en) * 2005-02-24 2007-12-05 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸
EP4551567A1 (en) 2022-07-05 2025-05-14 NewAmsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (cg-RX-API-DMAC7.html) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
DK1125929T3 (da) 2006-04-03
ES2254109T3 (es) 2006-06-16
JP3579345B2 (ja) 2004-10-20
PL344208A1 (en) 2001-06-04
IS5715A (is) 2001-05-31
HUP0004747A2 (hu) 2001-10-28
IL139849A (en) 2006-10-31
KR100408177B1 (ko) 2003-12-01
MA25223A1 (fr) 2001-07-02
BG105009A (en) 2001-11-30
CZ20004407A3 (cs) 2002-06-12
AU7178900A (en) 2001-05-31
CN1302800A (zh) 2001-07-11
AU784694B2 (en) 2006-06-01
EA200001129A2 (ru) 2001-06-25
ID28489A (id) 2001-05-31
GEP20022798B (en) 2002-09-25
CY1104989T1 (el) 2010-03-03
NO20006039D0 (no) 2000-11-29
EP1125929B1 (en) 2006-01-04
OA11494A (en) 2004-05-07
TNSN00230A1 (fr) 2005-11-10
DZ3079A1 (fr) 2004-10-24
UY26451A1 (es) 2001-06-29
JP2001163859A (ja) 2001-06-19
KR20010052012A (ko) 2001-06-25
AR029775A1 (es) 2003-07-16
EA200001129A3 (ru) 2001-10-22
GT200000190A (es) 2002-04-27
HU0004747D0 (cg-RX-API-DMAC7.html) 2001-02-28
HRP20000804A2 (en) 2001-06-30
CO5261552A1 (es) 2003-03-31
DE60025317T2 (de) 2006-08-03
EE200000659A (et) 2001-08-15
HK1038007A1 (en) 2002-03-01
DE60025317D1 (de) 2006-03-30
SK17792000A3 (sk) 2002-10-08
IL139849A0 (en) 2002-02-10
CA2327029C (en) 2005-08-09
HN2000000203A (es) 2001-06-13
AP2000002011A0 (en) 2000-12-31
US6313142B1 (en) 2001-11-06
NO20006039L (no) 2001-05-31
NZ508509A (en) 2001-06-29
CN1173953C (zh) 2004-11-03
ZA200006947B (en) 2002-05-27
EP1125929A1 (en) 2001-08-22
BR0005636A (pt) 2001-07-17
TW591016B (en) 2004-06-11
ATE315028T1 (de) 2006-02-15
PA8503801A1 (es) 2002-07-30
UA65615C2 (uk) 2004-04-15
CA2327029A1 (en) 2001-05-30
SG102603A1 (en) 2004-03-26
YU71500A (sh) 2003-02-28
HUP0004747A3 (en) 2002-12-28
EA003668B1 (ru) 2003-08-28

Similar Documents

Publication Publication Date Title
PE20010913A1 (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas
PE20001646A1 (es) BIFENILO QUE CONTIENEN COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE aP2
SE8700498D0 (sv) Novel pharmaceologically active compounds
PE20020722A1 (es) Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano
SE7906533L (sv) Pyrrolidinderivat
SE8406585D0 (sv) Benzoic acid derivatives
PE123499A1 (es) Derivados d-prolina
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
ATE284853T1 (de) Ureido-thiobuttersäurederivate als ppar-agonisten
SE8204237L (sv) Karbostyrilforeningar, kompositioner innehallande dessa samt forfaranden for framstellning derav
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
ATE253380T1 (de) Verfahren und mittel zur in-vivo erkennung von mundhöhlenkrebs und von präkanzerösen zuständen
ATE192152T1 (de) Piperidinderivate mit paf antagonistischer wirkung
KR870006034A (ko) 항균제로서의 5-아미노 및 5-하이드록시- 6,8-디플루오로퀴놀론
TR199901188T1 (xx) Aromatik veya heteroaromatik radikal ile de�i�tirilmi� bifenil t�revleri, ve bunlar� i�eren farmas�tik ve kozmetik bile�imler.
ATE189458T1 (de) Dipeptidische p-amidinobenzylamide mit n- terminalen sulfonyl- bzw. aminosulfonylresten
PT92647A (pt) Processo para a preparacao de 5-cloro-2-< { (3,4-dimetoxi-2-piridinil)-metil}-sulfinil>-1h-benzimidazol e de composicoes farmaceuticas que o contem
SE8701406D0 (sv) Aromatiska foreningar, deras framtellningsforfarande och deras anvendning inom human- och veterinermedicinen och inom kosmetiken
RO84816A (ro) Procedeu pentru prepararea unor 3-amino-sidnonimine substituite
FI831070L (fi) Salicylsyraderivat, foerfarande foer deras framstaellning, pao dessa foereningar baserade farmaceutprodukter och deras anvaendning
FI913034A0 (fi) Foerening med magsyrainhiberande effekt och foerfarande foer dess framstaellning.
GR3006834T3 (cg-RX-API-DMAC7.html)
NO970474D0 (no) N-substituerte azabicykloheptan-derivater egnet som neuroleptika
DK532679A (da) Fremgangsmaade til fremstilling af 2-aryl-3,4-diaza-bicyclo (4,1,0)hepten-(2)-on-(5).
SE9903996D0 (sv) New compounds

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed